Sort   by:  
 Page size 
BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all colorectal cancer (CRC) patients, and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as Encorafenib are ineffective due to MAP kinase pathway reactivation driven by BRAF dimeriza...
ORGANISM(S): Homo Sapiens 
2025-12-21 | PXD072281 |
BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all colorectal cancer (CRC) patients, and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as Encorafenib are ineffective due to MAP kinase pathway reactivation driven by BRAF dimeriza...
ORGANISM(S): Homo Sapiens 
2026-04-19 | PXD077365 |
The rate-limiting enzyme of salvage pathway for NAD+ synthesis, NAMPT, is aberrantly overexpressed in a variety of tumor cells and is a poor prognosis factor for patient survival. NAMPT plays a major role in tumor cell proliferation, acting concurrently as a NAD+ synthase and unexpectedly, an extrac...
ORGANISM(S): Homo Sapiens 
2021-09-13 | PXD028453 |
The rate-limiting enzyme of salvage pathway for NAD+ synthesis, NAMPT, is aberrantly overexpressed in a variety of tumor cells and is a poor prognosis factor for patient survival. NAMPT plays a major role in tumor cell proliferation, acting concurrently as an NAD+ synthase and unexpectedly, an extra...
ORGANISM(S): Homo Sapiens 
2022-01-24 | PXD031185 |
Sort   by:  
 Page size